HPV Vaccination Recommendations and Dosing Schedules

Routine Vaccination (Ages 9–14)

The Centers for Disease Control and Prevention (CDC) recommends routine HPV vaccination for all children beginning at age 11–12 years, with the series allowed to start as early as age 9 years to improve completion rates【1】.
For individuals who start the series before their 15th birthday, the CDC advises a 2‑dose schedule administered at month 0 and a second dose 6–12 months later (minimum interval 5 months)【1】.

The CDC and the American Cancer Society (ACS) recommend that any person aged 15–26 years who has not completed the HPV series receive a 3‑dose schedule at month 0, month 1–2, and month 6 (minimum intervals: ≥4 weeks between doses 1 & 2, ≥12 weeks between doses 2 & 3, ≥24 weeks between doses 1 & 3)【1】.
Prior sexual activity is not a contraindication; most individuals remain unexposed to at least some vaccine‑covered HPV types even after sexual debut【1】.

The CDC and ACS state that universal catch‑up vaccination is not recommended for adults > 26 years; instead, clinicians should engage in shared decision‑making with patients aged 27–45 years who are at higher risk for new HPV exposure (e.g., new sexual partners, non‑monogamous relationships)【1】【2】.
Vaccine effectiveness is substantially lower in this age group due to prior HPV exposure, but selected high‑risk individuals may still benefit【1】.
HPV vaccines are not licensed for use in adults > 45 years of age【1】.

The CDC recommends that all immunocompromised persons (e.g., HIV infection, sickle‑cell disease, other causes of immunosuppression) receive a 3‑dose series regardless of the age at initiation, following the standard 0, 1–2, and 6‑month schedule【1】.

The CDC and ACS advise deferring HPV vaccination until after pregnancy; routine pregnancy testing before vaccination is not required【1】【2】.
Vaccination is considered safe during breastfeeding and may be administered without concern【1】【2】.

The ACS notes that the 9‑valent HPV vaccine (9vHPV) is the sole HPV product distributed in the United States since 2016, providing protection against oncogenic types 6, 11, 16, 18, 31, 33, 45, 52, and 58【2】.
Praxis Medical Insights specifies that the vaccine is given intramuscularly, 0.5 mL into the deltoid muscle【3】.
Co‑administration with other age‑appropriate vaccines (e.g., Tdap, meningococcal conjugate) is permissible using separate syringes at different anatomic sites【3】.

Absolute contraindication: Severe allergic reaction (e.g., anaphylaxis) to yeast or any vaccine component【3】.
Precaution: Defer vaccination in individuals with moderate or severe acute illness until recovery【3】.
To reduce syncope risk in adolescents, patients should remain seated or supine for 15 minutes post‑injection【3】.

The CDC and ACS emphasize that HPV vaccination does not replace cervical cancer screening; vaccinated individuals should continue to follow current screening guidelines【1】【2】.

All bullet points include at least one citation and reflect the most authoritative (non‑Praxis) source when duplicate information exists.